Gclm (Glutamate Cysteine Ligase Modifier Subunit) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| GCLM (Glutamate-Cysteine Ligase Modifier Subunit) | |
|---|---|
| Protein Name | Glutamate-Cysteine Ligase Modifier Subunit |
| Gene | GCLM |
| UniProt | P48507 |
| PDB ID | 2F2K |
| Molecular Weight | 31 kDa |
| Localization | Cytosol |
| Protein Family | GCL family |
GCLM (Glutamate-Cysteine Ligase Modifier Subunit) is the modifier subunit of glutamate-cysteine ligase (GCL). GCLM enhances enzyme activity and modifies substrate affinity but lacks catalytic activity on its own.
GCLM:
GCLM:
Parkinson's Disease: GCLM variants affect glutathione synthesis capacity.
Alzheimer's Disease: GCLM polymorphisms may influence AD risk.
The study of Gclm (Glutamate Cysteine Ligase Modifier Subunit) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.